These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 15709899)

  • 21. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
    Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
    Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolcapone: a review of its use in the management of Parkinson's disease.
    Keating GM; Lyseng-Williamson KA
    CNS Drugs; 2005; 19(2):165-84. PubMed ID: 15697329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
    Guay DR
    Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of tolcapone in fluctuating Parkinson's disease.
    Stocchi F; De Pandis MF
    Clin Interv Aging; 2006; 1(4):317-25. PubMed ID: 18046910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease.
    Truong DD
    Clin Interv Aging; 2009; 4():109-13. PubMed ID: 19503773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
    Arnold G; Kupsch A
    Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
    Müller T; Kuhn W
    Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.
    Adler CH; Singer C; O'Brien C; Hauser RA; Lew MF; Marek KL; Dorflinger E; Pedder S; Deptula D; Yoo K
    Arch Neurol; 1998 Aug; 55(8):1089-95. PubMed ID: 9708959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.
    Marsala SZ; Gioulis M; Ceravolo R; Tinazzi M
    Clin Neuropharmacol; 2012; 35(4):185-90. PubMed ID: 22805229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolcapone: a novel approach to Parkinson's disease.
    Micek ST; Ernst ME
    Am J Health Syst Pharm; 1999 Nov; 56(21):2195-205. PubMed ID: 10565698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
    Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
    Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial.
    Rajput AH; Martin W; Saint-Hilaire MH; Dorflinger E; Pedder S
    Neurology; 1998 May; 50(5 Suppl 5):S54-9. PubMed ID: 9591523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
    Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
    Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
    Muhlack S; Herrmann L; Salmen S; Müller T
    J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
    Baas H; Zehrden F; Selzer R; Kohnen R; Loetsch J; Harder S
    Clin Pharmacokinet; 2001; 40(5):383-93. PubMed ID: 11432539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tolcapone in the management of Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(6):71-8. PubMed ID: 18688929
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease.
    Factor SA; Molho ES; Feustel PJ; Brown DL; Evans SM
    Clin Neuropharmacol; 2001; 24(5):295-9. PubMed ID: 11586115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
    Roberts JW; Cora-Locatelli G; Bravi D; Amantea MA; Mouradian MM; Chase TN
    Neurology; 1993 Dec; 43(12):2685-8. PubMed ID: 8255478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.
    Kurth MC; Adler CH; Hilaire MS; Singer C; Waters C; LeWitt P; Chernik DA; Dorflinger EE; Yoo K
    Neurology; 1997 Jan; 48(1):81-7. PubMed ID: 9008498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.